Discover and read the best of Twitter Threads about #blinding
Most recents (3)
Our new paper: »The sun was darkened for 17 days« (AD 797). An Interdisciplinary Exploration of Celestial Phenomena between #Byzantium, #Charlemagne, and a #VolcanicEruption. #MedievalWorlds 17/2022: doi.org/10.1553/mediev… (1/9)
#Byzanzforschung, @imafo_oeaw
#Byzanzforschung, @imafo_oeaw
The blinding of the #Byzantine Emperor Constantine VI in #Constantinople in August 797 CE and his overthrow by his mother Eirene was used as legitimation for the #coronation of the Frankish King #Charlemagne as emperor of the Romans on 25 December, 800. (2/9)
@imafo_oeaw
@imafo_oeaw
In #Byzantine sources, Constantine VI´s #blinding was linked with a spectacular #celestialmanifestation of divine disapproval: “The #sun was darkened for seventeen days and did not emit its rays so that ships lost course and drifted about.” (3/9)
#Byzanzforschung
#Byzanzforschung
Does blinding work in #antidepressant #RCT? Recently there were 2 papers on this topic with opposite conclusions. A🧵on #blinding and why #robustness #DataAnalytics may lead to better #science
The two papers are tinyurl.com/2p9atk4t (p1; by @AmeliaJScott, @LSharpeUSYD and @BenColagiuri) and tinyurl.com/mtmtx7m3 (p2; by @Toshi_FRKW and colleagues).
Their two conclusions:
-p1: "meta-analysis suggested that blinding was unsuccessful among participants and investigators."
-p2: "patients or assessors were unlikely to judge which treatment the patients were on."
-p1: "meta-analysis suggested that blinding was unsuccessful among participants and investigators."
-p2: "patients or assessors were unlikely to judge which treatment the patients were on."
Despite the importance of #blinding in medical research, most trials don't assess blinding integrity, partially because there is no method to adjust trial results for blinding integrity... until now! New preprint with implications for #microdose and #psychedelic research 🧪🧵👇
First, we define activated expectancy bias (AEB), which is an uneven distribution of expectancy effects between treatment arms due to patients recognizing their treatment allocation. AEB can be viewed as residual expectancy bias not eliminated by the trial’s blinding procedure.
The main idea behind AEB is that if treatment allocation can be deduced by participants, then, treatment expectancy can bias the outcomes in the same manner as it biases non-blinded trials, for example as in open-label trials.
